Abstract
A disorder of cholesterol homeostasis is one of the main initiating factors in the progression of atherosclerosis (AS). Metabolism and removal of excess cholesterol facilitates the prevention of foam cell formation. However, the failure of treatment with drugs (e.g. methotrexate, MTX) to effectively regulate progression of disease may be related to the limited drug bioavailability and rapid clearance by immune system. Thus, based on the inflammatory lesion “recruitment” properties of macrophages, MTX nanoparticles (MTX NPs) camouflaged with macrophage membranes (MM@MTX NPs) were constructed for the target to AS plaques. MM@MTX NPs exhibited a uniform hydrodynamic size around ~ 360 nm and controlled drug release properties (~ 72% at 12 h). After the macrophage membranes (MM) functionalized “homing” target delivery to AS plaques, MM@MTX NPs improved the solubility of cholesterol by the functionalized β-cyclodextrin (β-CD) component and significantly elevate cholesterol efflux by the loaded MTX mediated the increased expression levels of ABCA1, SR-B1, CYP27A1, resulting in efficiently inhibiting the formation of foam cells. Furthermore, MM@MTX NPs could significantly reduce the area of plaque, aortic plaque and cholesterol crystals deposition in ApoE−/− mice and exhibited biocompatibility. It is suggested that MM@MTX NPs were a safe and efficient therapeutic platform for AS.
Graphical Abstract
Similar content being viewed by others
Introduction
Atherosclerosis (AS) as a potential risk of myocardial infarction and stroke is mainly characterized by thickening of the arterial wall due to fibrous plaque. The progression of AS is a complex process that includes factors such as inflammation and lipid accumulation. When the lipid load in the monocyte-infiltrated subendothelial muscle layer is inadequately processed under the atherosclerotic lesion, overwhelming cholesterol deposition induces macrophages and smooth muscle cells (SMCs) to become pathological foam cells while forming fatty streaks [1, 2]. Subsequently, fibrous plaques are gradually formed, reducing the arterial lumen area. Cholesterol crystal (CCs) deposition played an important role during the course of atherosclerosis [3]. Some studies have shown that CCs initially arise and accumulate in the chocolate-cell lysosomes and then are gradually deposited in atherosclerotic lesions with apoptosis of the chocolate-cells [4, 5]. CCs induces the secretion of inflammatory cytokines, such as interleukin-1β (IL-1β) and tumor necrosis factor (TNF-α), which in turn enhances monocyte infiltration and induces apoptosis in foam cells, leading to chronic inflammation [6,7,8].
It is well-known that only the free cholesterol can be further metabolized and intracellularly efflux by cholesterol transport proteins in lysosome, such as Niemann-Pick C-type associated protein (NPC) 1 or 2. As soon as free cholesterol has been converted to CCs, the CCs cannot be trafficked via NPC-1 or NPC-2, which results in over-loading of CCs in lysosome and consequent apoptosis [9]. Thus, preventing CCs formation or cleavage CCs from lysosomes is a widely used strategy in the clinical treatment of AS. Because of the unique molecular structure of β-Cyclodextrin (β-CD) can efficient loading or enhance cholesterol solubility through “host–guest” interactions, i.e., the β-CD lumen closely matches the cholesterol molecule [10]. Therefore, β-CD is considered the potentially effective therapeutic agent to enhance cholesterol efflux for the promising AS treatment.
Methotrexate (MTX) is an anti-inflammatory drug for the treatment of diseases such as rheumatoid arthritis and psoriatic arthritis. Recently, researchers have suggested that MTX could be effective in treating the chronic inflammatory disease AS [11, 12]. MTX has been proven to inhibit foam cell formation by MTX-induced upregulation of scavenger receptor B1 (SR-B1), ATP binding cassette transporter A1 (ABCA1) and cholesterol 27-hydroxylase (CYP27A1), which efficiently induces the cholesterol efflux [11, 13]. However, further usage of the hydrophobic MTX is greatly hindered because of the low solubility induced by the low bioavailability and the serious adverse effects in the blood [12]. Nanotechnology offers a pathway for the systematic delivery of multiple drugs. Compared to free drugs, nanomedicines can significantly increase their efficacy and reduce side effects [14,15,16,In vivo atherosclerotic plaques targeting and long-term circulation test ApoE−/− mice were fed a high-fat diet (HFD) for 2 months. DiD NPs and MM@DiD NPs were administered via the tail vein at DiD dose of 2 mg/kg. After 24 h, the mice were euthanized and perfused with precooled PBS containing 4% PFA. Each aorta and the main organs were isolated for imaging using a Xenogen IVIS 200 system (Xenogen, IVIS 200, USA). C57BL/6 mice weighing 25 ± 2 g were subjected to in vivo long-term cycling tests. Briefly, DiD NPs and MM@DiD NPs (200 μL, 2 mg/mL) were injected intravenously and 30 μL of blood was collected rapidly from the tail after 1 min, 1, 6, 12, 24 and 48 h. Blood samples were diluted with 30 μL of PBS containing EDTA-K2 in a 96-well plate and fluorescence intensity was measured using a microplate apparatus (Tecan, M1000 PRO, USA). ApoE−/− mice after 8 weeks of HFD feeding were randomized into 4 groups (5 mice per group) and dosed for 30 days by tail vein injection every three days. In the treatment groups, mice were administered PBS, free MTX, MTX NPs, or MM@MTX NPs at a dose of 5 mg/kg of MTX. At the end stage of the treatment, the ApoE−/− mice were euthanized. The pathological evolution was assessed by measuring the lesion area of atherosclerotic plaques in the aorta from the heart to the iliac bifurcation. Briefly, each aorta was fixed with PFA (4% PBS) for 1 h. After washing the peripheral tissue, the aorta was opened longitudinally and the whole aorta was then stained with ORO to quantify the plaque area. The extent of atherosclerotic plaque in the aortic root was determined in the same way. Atherosclerotic plaque areas were quantified using Adobe Photoshop 2021 software. Aortic root histology and immunohistochemical staining: Aortic roots were fixed in 4% PFA for 1 h. Frozen sections were prepared and stained with toluidine blue to quantify the necrotic core. For analysis of cholesterol and cholesteryl esters, sections were placed in a solution of ferric ammonium sulphate and reacted at room temperature for 3 days. An acetic acid-sulphate mixture was added and subsequently observed under the microscope. For immunohistochemistry, sections were immersed in 3% hydrogen peroxide and 100% methanol for 20 min to inhibit endogenous peroxidase activity, followed by blocking with 1% bovine serum albumin in PBS containing 0.3% Triton X-100 for 60 min. CD68, F4/80, ABCA1, SR-B1, CYP27A1, IL-1β, TNF-α and IFN-β antibodies were co-incubated for macrophage quantification. Histological and immunohistochemical quantification was performed using Adobe Photoshop 2020 software. Hematoxylin–eosin (H&E) staining was used to analyse sections of major organs. Complete blood routine analysis and serum biochemistry analysis: Blood was collected and analyzed using an automated hematology analyzer (Sysmex Co., Sysmex KX-21, Japan) after treatment. The data obtained are reported as the mean ± SD in this study. GraphPad Prism Version 7.0 software (GraphPad Software, GraphPad Prism 7.0, USA) was used for the statistical analysis. One-way or two-way analysis of variance (ANOVA) by Tukey’s test was used to reveal differences between the groups. The difference significance levels were set at *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. n.s., no significance.Treatment of atherosclerosis in ApoE−/− mice
Statistical analysis
Availability of data and materials
All data contained in the study are in this article.
References
Libby P. Changing concepts of atherogenesis. J Intern Med. 2000;247:349–58.
Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340:115–26.
Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357–61.
Varsano N, Dadosh T, Kapishnikov S, Pereiro E, Shimoni E, ** X, Kruth HS, Leiserowitz L, Addadi L. Development of correlative cryo-soft X-ray tomography and stochastic reconstruction microscopy. A study of cholesterol crystal early formation in cells. J Am Chem Soc. 2016;138:14931–40.
Tangirala RK, Jerome WG, Jones NL, Small DM, Johnson WJ, Glick JM, Mahlberg FH, Rothblat GH. Formation of cholesterol monohydrate crystals in macrophage-derived foam cells. J Lipid Res. 1994;35:93–104.
Warnatsch A, Ioannou M, Wang Q, Papayannopoulos V. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science. 2015;349:316–20.
Corr EM, Cunningham CC, Dunne A. Cholesterol crystals activate Syk and PI3 kinase in human macrophages and dendritic cells. Atherosclerosis. 2016;251:197–205.
Zhang Y, Gong F, Wu Y, Hou S, Xue L, Su Z, Zhang C. Poly-β-cyclodextrin supramolecular nanoassembly with a pH-sensitive switch removing lysosomal cholesterol crystals for antiatherosclerosis. Nano Lett. 2021;21:9736–45.
Sleat DE, Wiseman JA, El-Banna M, Price SM, Verot L, Shen MM, Tint GS, Vanier MT, Walkley SU, Lobel P. Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport. Proc Natl Acad Sci. 2004;101:5886–91.
Mahjoubin-Tehran M, Kovanen PT, Xu S, Jamialahmadi T, Sahebkar A. Cyclodextrins: potential therapeutics against atherosclerosis. Pharmacol Ther. 2020;214: 107620.
Coomes E, Chan ES, Reiss AB. Methotrexate in atherogenesis and cholesterol metabolism. Cholesterol. 2011;2011: 503028.
Di Francesco V, Gurgone D, Palomba R, Ferreira MFMM, Catelani T, Cervadoro A, Maffia P, Decuzzi P. Modulating lipoprotein transcellular transport and atherosclerotic plaque formation in ApoE–/– mice via nanoformulated lipid-methotrexate conjugates. ACS Appl Mater Interfaces. 2020;12:37943–56.
Ronda N, Greco D, Adorni MP, Zimetti F, Favari E, Hjeltnes G, Mikkelsen K, Borghi MO, Favalli EG, Gatti R, et al. Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arthr Rheumatol. 2015;67:1155–64.
Wu W, Wang J, Lin Z, Li X, Li J. Tumor-acidity activated surface charge-conversion of polymeric nanocarriers for enhanced cell adhesion and targeted drug release. Macromol Rapid Commun. 2014;35:1679–84.
Li X, Zheng B-Y, Ke M-R, Zhang Y, Huang J-D, Yoon J. A tumor-pH-responsive supramolecular photosensitizer for activatable photodynamic therapy with minimal in vivo skin phototoxicity. Theranostics. 2017;7:2746–56.
Wu W, Zhang Q, Wang J, Chen M, Li S, Lin Z, Li J. Tumor-targeted aggregation of pH-sensitive nanocarriers for enhanced retention and rapid intracellular drug release. Polym Chem. 2014;5:5668–79.
Liao J, Zheng H, Fei Z, Lu B, Zheng H, Li D, **ong X, Yi Y. Tumor-targeting and pH-responsive nanoparticles from hyaluronic acid for the enhanced delivery of doxorubicin. Int J Biol Macromol. 2018;113:737–47.
Obaid E, Wu S, Zhong Y, Yan M, Zhu L, Li B, Wang Y, Wu W, Wang G. pH-Responsive hyaluronic acid-enveloped ZIF-8 nanoparticles for anti-atherosclerosis therapy. Biomater Sci. 2022;10:4837–47.
Zhong Y, Qu K, Yan W, Zhang K, Qin X, Wang Y, Yan M, Wu S, Zhu L, Abdo Mohammed Saad Obaid E, et al. Overexpressed VLA-4 on endothelial cell membrane camouflaging the pathological reactive oxygen species responsive prodrug to enhance target therapy for atherosclerosis. Chem Eng J. 2022;442: 136198.
Wijaya A, Wang Y, Tang D, Zhong Y, Liu B, Yan M, Jiu Q, Wu W, Wang G. A study of lovastatin and l-arginine co-loaded PLGA nanomedicine for enhancing nitric oxide production and eNOS expression. J Mater Chem B. 2022;10:607–24.
Liu B, Yan W, Luo L, Wu S, Wang Y, Zhong Y, Tang D, Maruf A, Yan M, Zhang K, et al. Macrophage membrane camouflaged reactive oxygen species responsive nanomedicine for efficiently inhibiting the vascular intimal hyperplasia. J Nanobiotechnol. 2021;19:374.
Wang Y, Zhang K, Li T, Maruf A, Qin X, Luo L, Zhong Y, Qiu J, McGinty S, Pontrelli G, et al. Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications. Theranostics. 2021;11:164–80.
Zhu L, Zhong Y, Wu S, Yan M, Cao Y, Mou N, Wang G, Sun D, Wu W. Cell membrane camouflaged biomimetic nanoparticles: focusing on tumor theranostics. Materials Today Bio. 2022;14: 100228.
Pei Q, Hu X, Zheng X, Liu S, Li Y, **g X, **e Z. Light-activatable red blood cell membrane-camouflaged dimeric prodrug nanoparticles for synergistic photodynamic/chemotherapy. ACS Nano. 2018;12:1630–41.
Zhao H, Li L, Zhang J, Zheng C, Ding K, **ao H, Wang L, Zhang Z. C-C chemokine ligand 2 (CCL2) recruits macrophage-membrane-camouflaged hollow bismuth selenide nanoparticles to facilitate photothermal sensitivity and inhibit lung metastasis of breast cancer. ACS Appl Mater Interfaces. 2018;10:31124–35.
Hamidzadeh K, Christensen SM, Dalby E, Chandrasekaran P, Mosser DM. Macrophages and the recovery from acute and chronic inflammation. Annu Rev Physiol. 2017;79:567–92.
Thamphiwatana S, Angsantikul P, Escajadillo T, Zhang Q, Olson J, Luk BT, Zhang S, Fang RH, Gao W, Nizet V, Zhang L. Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management. Proc Natl Acad Sci. 2017;114:11488–93.
Xuan M, Shao J, Dai L, He Q, Li J. Macrophage cell membrane camouflaged mesoporous silica nanocapsules for in vivo cancer therapy. Adv Healthcare Mater. 2015;4:1645–52.
Li R, He Y, Zhu Y, Jiang L, Zhang S, Qin J, Wu Q, Dai W, Shen S, Pang Z, Wang J. Route to rheumatoid arthritis by macrophage-derived microvesicle-coated nanoparticles. Nano Lett. 2019;19:124–34.
Peng R, Ji H, ** L, Lin S, Huang Y, Xu K, Yang Q, Sun D, Wu W. Macrophage-based therapies for atherosclerosis management. J Immunol Res. 2020;2020:8131754.
França CN, Izar MCO, Hortêncio MN, do Amaral JB, Ferreira CES, Tuleta ID, Fonseca FAH. Monocyte subtypes and the CCR2 chemokine receptor in cardiovascular disease. Clinical Science. 2017;131:1215–1224.
Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13:709–21.
Sukumar UK, Bose RJC, Malhotra M, Babikir HA, Afjei R, Robinson E, Zeng Y, Chang E, Habte F, Sinclair R, et al. Intranasal delivery of targeted polyfunctional gold–iron oxide nanoparticles loaded with therapeutic microRNAs for combined theranostic multimodality imaging and presensitization of glioblastoma to temozolomide. Biomaterials. 2019;218: 119342.
Barbosa JAA, Zoppi A, Quevedo MA, De Melo PN, De Medeiros ASA, Streck L, De Oliveira AR, Fernandes-Pedrosa MF, Longhi MR, Da Silva-Júnior AA. Triethanolamine stabilization of methotrexate-β-cyclodextrin interactions in ternary complexes. Int J Mol Sci. 2014;15:17077–99.
Gorjikhah F, Azizi Jalalian F, Salehi R, Panahi Y, Hasanzadeh A, Alizadeh E, Akbarzadeh A, Davaran S. Preparation and characterization of PLGA-β-CD polymeric nanoparticles containing methotrexate and evaluation of their effects on T47D cell line. Artif Cells Nanomed Biotechnol. 2017;45:432–40.
Yuan C, ** Z, Xu X. Inclusion complex of astaxanthin with hydroxypropyl-β-cyclodextrin: UV, FTIR, 1H NMR and molecular modeling studies. Carbohyd Polym. 2012;89:492–6.
Giri BR, Yang HS, Song I-S, Choi H-G, Cho JH, Kim DW. Alternative methotrexate oral formulation: enhanced aqueous solubility, bioavailability, photostability, and permeability. Pharmaceutics. 2022;14:2022.
Li Y, Che J, Chang L, Guo M, Bao X, Mu D, Sun X, Zhang X, Lu W, **e J. CD47- and Integrin α4/β1-comodified-macrophage-membrane-coated nanoparticles enable delivery of colchicine to atherosclerotic plaque. Adv Healthc Mater. 2022;11:2101788.
Boniakowski AE, Kimball AS, Joshi A, Schaller M, Davis FM, denDekker A, Obi AT, Moore BB, Kunkel SL, Gallagher KA. Murine macrophage chemokine receptor CCR2 plays a crucial role in macrophage recruitment and regulated inflammation in wound healing. Eur J Immunol. 2018;48:1445–55.
Fantuzzi L, Tagliamonte M, Gauzzi MC, Lopalco L. Dual CCR5/CCR2 targeting: opportunities for the cure of complex disorders. Cell Mol Life Sci. 2019;76:4869–86.
Breslow R, Zhang B. Cholesterol recognition and binding by cyclodextrin dimers. J Am Chem Soc. 1996;118:8495–6.
Gao C, Huang Q, Liu C, Kwong CHT, Yue L, Wan J-B, Lee SMY, Wang R. Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines. Nat Commun. 2020;11:2622.
Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–74.
Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17:1410–22.
Noels H, Weber C, Koenen RR. Chemokines as therapeutic targets in cardiovascular disease. Arterioscler Thromb Vasc Biol. 2019;39:583–92.
Namiki M, Kawashima S, Yamashita T, Ozaki M, Hirase T, Ishida T, Inoue N, Hirata K, Matsukawa A, Morishita R, et al. Local overexpression of monocyte chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesion. Arteriosclerosis Thrombosis Vascul Biol. 2002;22:115–20.
Georgakis MK, Bernhagen J, Heitman LH, Weber C, Dichgans M. Targeting the CCL2–CCR2 axis for atheroprotection. Eur Heart J. 2022;43:1799–808.
Liu Y, Fu S, Lin L, Cao Y, **e X, Yu H, Chen M, Li H. Redox-sensitive Pluronic F127-tocopherol micelles: synthesis, characterization, and cytotoxicity evaluation. Int J Nanomed. 2017;12:2635–44.
Ramasamy T, Haidar ZS, Tran TH, Choi JY, Jeong JH, Shin BS, Choi HG, Yong CS, Kim JO. Layer-by-layer assembly of liposomal nanoparticles with PEGylated polyelectrolytes enhances systemic delivery of multiple anticancer drugs. Acta Biomater. 2014;10:5116–27.
Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf. 2005;4:723–30.
Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15:104–16.
Westerterp M, Murphy AJ, Wang M, Pagler TA, Vengrenyuk Y, Kappus MS, Gorman DJ, Nagareddy PR, Zhu X, Abramowicz S, et al. Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice. Circ Res. 2013;112:1456–65.
Xu Y, Liu Q, Xu Y, Liu C, Wang X, He X, Zhu N, Liu J, Wu Y, Li Y, et al. Rutaecarpine suppresses atherosclerosis in ApoE-/- mice through upregulating ABCA1 and SR-BI within RCT. J Lipid Res. 2014;55:1634–47.
Zhou Y, Zhou H, Hua L, Hou C, Jia Q, Chen J, Zhang S, Wang Y, He S, Jia E. Verification of ferroptosis and pyroptosis and identification of PTGS2 as the hub gene in human coronary artery atherosclerosis. Free Radical Biol Med. 2021;171:55–68.
Welsh P, Grassia G, Botha S, Sattar N, Maffia P. Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? Br J Clin Pharmacol. 2017;174:3898–913.
Jiang Q, Liu Y, Guo R, Yao X, Sung S, Pang Z, Yang W. Erythrocyte-cancer hybrid membrane-camouflaged melanin nanoparticles for enhancing photothermal therapy efficacy in tumors. Biomaterials. 2019;192:292–308.
Li C, Dou Y, Chen Y, Qi Y, Li L, Han S, ** T, Guo J, Chen J, Zhang J. Site-specific MicroRNA-33 antagonism by pH-responsive nanotherapies for treatment of atherosclerosis via regulating cholesterol efflux and adaptive immunity. Adv Func Mater. 2020;30:2002131.
Xu S, Ilyas I, Little PJ, Li H, Kamato D, Zheng X, Luo S, Li Z, Liu P, Han J, et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacol Rev. 2021;73:924–67.
Mora E, Guglielmotti A, Biondi G, Sassone-Corsi P. Bindarit. Cell Cycle. 2012;11:159–69.
Luo L, Wu W, Sun D, Dai H-B, Wang Y, Zhong Y, Wang J-X, Maruf A, Nurhidayah D, Zhang X-J, et al. Acid-activated melittin for targeted and safe antitumor therapy. Bioconjug Chem. 2018;29:2936–44.
Acknowledgements
This work was supported by grants from the National Natural Science Foundation of China (31971301, 32171324), Fundamental Research Funds for the National Key R&D Project (2022YFF0710700), Natural Science Foundation of Chongqing (cstc2021jcyj-msxmX0149), Postdoctoral Research Foundation of China (2022M710526, 2022M720574), Fundamental Research Funds for Central Universities (2022CDJXY-026, 2020CDJQY-A061, 2018CDHB1B08), **Feng Laboratory of Chongqing (jfkyjf202203001). In addition, we would like to thank Mr. Zhang Bin at Analytical and Testing Center of Chongqing University for their assistance with TEM.
Author information
Authors and Affiliations
Contributions
LZ: Review, software, methodology and writing draft. HJL: Review and validation. JYL: Biocompatibility study YZ: Conceptualization. SW: Biocompatibility study. MY: MTs assay and review. SN: Biocompatibility study. KZ: Animal study. GXW: Validation and resources. XQ: HE staining. DQY: Validation and resources. KQ: Animal study. WW: Supervision, review and editing.
Corresponding authors
Ethics declarations
Ethics approval and consent to participate
All animal care and experimental protocols were conducted under the approval of the Chongqing University Institutional Animal Care and Use Committee (ACUC) (IACUC issue number: COU-IACUC-RE-202109-002).
Competing interests
No conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Additional file 1: Figure S1.
Schematic diagram of MPEG-CD synthesis. Figure S2. The FT-IR of MPEG-CD. Figure S3. 1H-NMR of MPEG-CD. Figure S4. MTX NPs in aqueous solution. Figure S5. 1H-NMR spectra of MTX, MPEG-CD and MPEG-CD@MTX (MTX NPs). Figure S6. 2D NOESY spectrum of MPEG-CD@MTX inclusion complex (MTX NPs). Figure S7. Coomassie brilliant blue bands of macrophages, MM and MM@MTX NPs. Figure S8. Cell viability of (A) ECs, (B) RAW 264.7 cells and (C) LPS-induced RAW 264.7 cells after incubation with free MTX, MTX NPs or MM@MTX NPs for 24 h. (***p < 0.001; n.s., no significance.). Figure S9. Hemolysis percentage and visual images of the hemolysis test with free MTX, MTX NPs or MM@MTX NPs. Figure S10. Toxic effects of different concentrations of free MTX, MTX NPs and MM@MTX NPs on zebrafish embryos. Figure S11. Quantification of (A) IL-1β, (B) TNF-α and (C) IFN-β mRNA levels in RAW 264.7 cells by real-time PCR. (n = 5, *p < 0.05, **p < 0.01, ***p < 0.001; n.s., no significance). Figure S12. The body weight change of mice during 30 days. Figure S13. Blood cell counts of immune-associated cells including (A) lymphocyte, (B) monocyte and (C) neutrophil. Table S1. Comparative 1H-NMR chemical shifts of (δ, ppm) studies of free MTX, β-CD, MPEG-CD@MTX inclusion complex (MTX NPs), and their complexation induced shifts (Δδ). (Δδ ppm = δ complex–δ free). (ND: no detected).
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Zhu, L., Li, H., Li, J. et al. Biomimetic nanoparticles to enhance the reverse cholesterol transport for selectively inhibiting development into foam cell in atherosclerosis. J Nanobiotechnol 21, 307 (2023). https://doi.org/10.1186/s12951-023-02040-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12951-023-02040-9